Receptors, Thrombopoietin
"Receptors, Thrombopoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that are specific for THROMBOPOIETIN. They signal through interaction with JANUS KINASES such as JANUS KINASE 2.
MeSH Number(s)
D12.776.543.750.705.852.610
D23.050.301.264.035.881
D23.101.100.110.883
Concept/Terms
Receptors, Thrombopoietin- Receptors, Thrombopoietin
- Thrombopoietin Receptors
- MPL Ligand Receptor
- Ligand Receptor, MPL
- Receptor, MPL Ligand
- Thrombopoietin Receptor
- Receptor, Thrombopoietin
- Antigens, CD110
- CD110 Antigens
Below are MeSH descriptors whose meaning is more general than "Receptors, Thrombopoietin".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Thrombopoietin [D12.776.543.750.705.852.610]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Receptors, Thrombopoietin [D23.050.301.264.035.881]
- Biological Markers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Receptors, Thrombopoietin [D23.101.100.110.883]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Thrombopoietin".
This graph shows the total number of publications written about "Receptors, Thrombopoietin" by people in Harvard Catalyst Profiles by year, and whether "Receptors, Thrombopoietin" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 4 | 4 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 3 | 4 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 3 | 4 |
| 2013 | 3 | 7 | 10 |
| 2014 | 2 | 3 | 5 |
| 2015 | 2 | 6 | 8 |
| 2016 | 5 | 3 | 8 |
| 2017 | 3 | 3 | 6 |
| 2018 | 3 | 5 | 8 |
| 2019 | 2 | 3 | 5 |
| 2020 | 4 | 3 | 7 |
| 2021 | 5 | 7 | 12 |
| 2022 | 1 | 4 | 5 |
Below are the most recent publications written about "Receptors, Thrombopoietin" by people in Profiles.
-
Longitudinal study of 2 patients with cyclic thrombocytopenia, STAT3 and MPL mutations. Blood Adv. 2023 Jan 10; 7(1):190-194.
-
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem. Hematology Am Soc Hematol Educ Program. 2022 12 09; 2022(1):286-295.
-
Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs. Blood. 2022 09 15; 140(11):1291-1304.
-
An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia. Expert Rev Clin Immunol. 2022 08; 18(8):783-791.
-
Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies. Neuro Oncol. 2022 06 01; 24(6):964-973.
-
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. Br J Haematol. 2022 05; 197(3):359-366.
-
Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials. Pediatr Blood Cancer. 2022 03; 69(3):e29447.
-
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev. 2022 05; 53:100909.
-
TPO versus TPO: the good, the bad, and the to be determined. Br J Haematol. 2021 12; 195(5):653-654.
-
Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. Ann Hematol. 2021 Dec; 100(12):2879-2887.